ABSCIEX和ARUP实验室联合开发激素分析临床研究新方法

　　2011年2月7日——全球生命科学分析技术的领导者AB SCIEX 公司，今天宣布与美国主要的临床基准实验室ARUP 实验室合作，共同开发新的测试方法供全球实验室采用，从而提高对激素的分析水平，在使用了AB SCIEX的QTRAP^® 5500质谱技术后，ARUP的研究人员得到了以前临床研究中无法获得的结果。这一进展有望获得更好的结果，用以提高医疗保健的水平。2001年2月初，在圣地亚哥举办的临床实验室质谱应用研讨会（Mass Spectrometry Applications for the Clinical Laboratory (MSACL) conference）上，AB SCIEX公司展示了其QTRAP^® 技术。

QTrap 5500质谱仪

　　与领先的临床基准实验室合作旨在推进全行业逐渐使用质谱仪器来进行激素分析。因为很多激素的存在丰度极低，免疫测试方法往往被干扰所困，无法获得精确的测量结果。为应对这一挑战，ARUP转向使用QTRAP^® 技术获得更高水平的灵敏度——这一点在低丰度激素的精确定量中很有必要，尤其对于游离激素；同时，用Qtrap同一台仪器的定性能力来进行结果的验证也很重要。

　　在基于质谱的临床研究中，AB SCIEX 公司提供当今市场上最高灵敏度的仪器，并提供一个简单的、四步法的工作流程。在一个平台上，AB SCIEX QTRAP^® 5500 系统集高灵敏度、高速度于一身；集成了定性和定量分析能力，代表着更高类型的三重四极杆仪器。在同AB SCIEX科研人员的合作中，ARUP的研究人员用QTRAP^® 技术开发了新的测试方法，AB SCIEX公司计划把这一方法转变成预先配置的iMethod™ 测试方法，使之能够易于下载到AB SCIEX Cliquid^® 软件中。在临床研究中，可立快Cliquid^® 软件可显著简化高端质谱技术的操作，让使用更方便。

　　Alan Rockwood博士，ARUP 实验室质谱室的科学主管

　　“在ARUP的质谱实验室中，我们的任务就是获得尽可能低的定量分析的检出限，这样我们才能为临床研究提供更好的结果。在合作中，AB SCIEX的科学家们花时间来了解我们苛刻的要求，使我们更好地应用质谱技术来完成我们的目标。通过提供比从前更准确的答案，我们正在努力为提高医疗服务提供支持。”

　　Joe Anacleto, AB SCIEX应用市场和临床研究业务部副总裁兼总经理

　　“向基于质谱的临床研究转变还将加速。像ARUP这样领先的临床基准实验室，使用QTRAP^® 技术进行方法开发，使AB SCIEX技术提供的高灵敏度变得更主要。通过成为临床研究者值得信赖的合作伙伴，AB SCIEX能够令实验室更轻松地使用质谱、并获得更好的结果。”

　　关于AB SCIEX

　　AB SCIEX是生命科学分析技术开发领域的全球领先企业，帮助科学家应对复杂的科学挑战。公司提供科学仪器、软件和服务，用于发现新药、促进医学科学发展、 保护食品供应链和环境。AB SCIEX的技术解决方案结合了最高的性能和最高的稳定性，确保我们的用户进行科学发现、可靠地传递结果和提高生命质量。AB SCIEX拥有近超过20年的创新历史，在市场中一直出于领先地位，其前身为美国应用生物系统公司（Applied Biosystems）和美迪希（MDS）实验仪器公司的合资企业。更多资料请访问官网：www.absciex.com。

　　本网收录相关仪器：QTRAP5500 四极杆-线性阱杂交质谱仪

      参考英文原文　　

AB SCIEX and ARUP Laboratories Collaborate to Develop New Clinical Research Methods for Hormone Analysis

　　AB SCIEX, a global leader in life science analytical technologies, today announced a collaboration with ARUP Laboratories, a major clinical reference laboratory in the United States, to develop new test methods that clinical research laboratories around the world can adopt to improve hormone analysis. ARUP researchers are using AB SCIEX QTRAP^® 5500 mass spectrometry technology to obtain results that were previously unavailable to clinical researchers. This advancement is expected to help deliver better answers that can be used to improve healthcare. AB SCIEX is exhibiting QTRAP^® technology at Mass Spectrometry Applications for the Clinical Laboratory (MSACL) conference in San Diego this week.

　　This collaboration with a leading clinical reference laboratory is intended to help drive the industry-wide move toward increasingly using mass spectrometry to conduct hormone analysis. Because many hormones exist in extremely low abundance, immunoassay-based approaches are often plagued by interferences, preventing them from obtaining accurate measurements. To address this challenge, ARUP turned to QTRAP^® technology to obtain a higher level of sensitivity, which is needed to perform the most accurate quantitation of low abundant hormones, especially free hormones, while confirming the results with qualitative capabilities within the same system.

　　AB SCIEX provides the highest sensitivity instrumentation on the market today as part of a simple, four-step workflow for mass spectrometry-based clinical research. The AB SCIEX QTRAP^® 5500 System combines high sensitivity and speed on a platform that integrates quantitative and qualitative analysis, representing a better type of triple quadrupole. In collaboration with AB SCIEX scientists, ARUP researchers are using this technology to develop new test methods that AB SCIEX plans to turn into pre-configured iMethod™ Tests available for easy download into AB SCIEX Cliquid^® Software, which is a software application that significantly simplifies the use of advanced mass spectrometry technology for clinical research.

　　Alan Rockwood, Ph.D., Scientific Director of the Mass Spectrometry Lab at ARUP Laboratories

　　“Our mission in the mass spectrometry lab of ARUP is to push the limits of quantitation as low as we can, so we can deliver better results for clinical research. Our collaboration with AB SCIEX, whose scientists have taken the time to understand our stringent requirements, gives us access to mass spectrometry technology that helps us to fulfill our purpose. By providing more accurate answers than previously possible, we are supporting efforts to improve medical care.”

　　Joe Anacleto, Vice President and General Manager of the Applied Markets and Clinical Research Business, AB SCIEX

　　“The shift to mass spectrometry-based clinical research continues to rapidly accelerate. To have a leading clinical reference laboratory such as ARUP Laboratories utilize QTRAP^® technology for method development reinforces the importance of high sensitivity that AB SCIEX technology delivers. By being a trusted partner with clinical researchers, AB SCIEX is able to make it easier for laboratories to adopt mass spectrometry and obtain better answers.”

　　About AB SCIEX

　　AB SCIEX is a global leader in the development of life science analytical technologies that help answer complex scientific challenges. The company provides scientific instrumentation, software and services used to discover new drugs, advance medical science and protect the food supply and the environment. AB SCIEX technology solutions combine the highest performance with the highest reliability to enable our customers to fuel scientific discovery, deliver results with confidence and improve the quality of life. The company has a more than 20-year history of innovation and market leadership as the former Applied Biosystems/MDS Analytical Technologies joint venture. For more information about AB SCIEX, go to www.absciex.com.

　　英文原文链接：AB SCIEX and ARUP Laboratories Collaborate to Develop New Clinical Research Methods for Hormone Analysis